Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery
Public ClinicalTrials.gov record NCT01234935. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Open-Label, Randomized, Phase II Trial of Adjuvant Dasatinib Plus Gemcitabine Versus Single-Agent Gemcitabine in Patients With Resected Pancreatic Adenocarcinoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving dasatinib together with gemcitabine hydrochloride is more effective than gemcitabine hydrochloride alone in treating pancreatic cancer. PURPOSE: This randomized phase II trial is studying how well giving dasatinib together with gemcitabine hydrochloride works compared to giving gemcitabine hydrochloride alone in treating patients with pancreatic cancer previously treated with surgery.
Study identification
- NCT ID
- NCT01234935
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 8 participants
Conditions and interventions
Conditions
Interventions
- dasatinib Drug
- gemcitabine hydrochloride Drug
- laboratory biomarker analysis Other
- mutation analysis Genetic
- nucleic acid sequencing Genetic
- immunohistochemistry staining method Other
Drug · Other · Genetic
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 12, 2011
- Primary completion
- Nov 26, 2017
- Completion
- Nov 26, 2017
- Last update posted
- Jan 8, 2018
2011 – 2017
United States locations
- U.S. sites
- 17
- U.S. states
- 4
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Central Hematology Oncology Medical Group, Inc. | Alhambra | California | 91801 | — |
| TORI FULLERTON (St. Jude Heritage Healthcare Virginia K. Crosson Cancer Center) | Fullerton | California | 92835 | — |
| Pacific Shores Medical Group | Long Beach | California | 90813 | — |
| UCLA medical center | Los Angeles | California | 90024-3417 | — |
| Translational Oncology Research International (TORI) Network | Los Angeles | California | 90095 | — |
| TORI NORTHRIDGE (North Valley Hematology/Oncology Medical Group) | Northridge | California | 91325 | — |
| UCLA Pasadena | Pasadena | California | — | — |
| TORI Inland Valley (Wilshire Oncology Medical Group, Inc. ) | Pomona | California | 91767 | — |
| TORI REDONDO BEACH (Cancer Care Associates Medical Group, Inc.) | Redondo Beach | California | 90277 | — |
| TORI SANTA BARBARA I (Santa Barbara Hematology Oncology Medical Group, Inc.) | Santa Barbara | California | 93105 | — |
| TORI SANTA BARBARA II (SANSUM Clinic) | Santa Barbara | California | 93105 | — |
| TORI SANTA MARIA (Central Coast Medical Oncology Corporation) | Santa Maria | California | 93454 | — |
| UCLA Valencia | Valencia | California | — | — |
| Suburban Hematology-Oncology Associates, P.A. | Lawrenceville | Georgia | 30045 | — |
| Northwest Georgia Oncology Centers, P.C. | Marietta | Georgia | 30060 | — |
| Chevy Chase Healthcare Management, LLC | Chevy Chase | Maryland | 20815 | — |
| Comprehensive Cancer Centers of Nevada | Las Vegas | Nevada | 89109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01234935, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 8, 2018 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01234935 live on ClinicalTrials.gov.